Karissa Mishler, APRN
Psychiatric/Mental Health · Manhattan, KSNPI 1235861386
Payments from drug & device makers
Across 179 payments — averaging $18.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$637
- Supernus Pharmaceuticals, Inc.$512
- AbbVie$483
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$309
- Otsuka America Pharmaceutical, Inc.$201
- Lundbeck LLC$154
- plus $961 from 12 others
What the payments were for
- Food & beverage$3,258100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 31 | $637 |
| Supernus Pharmaceuticals, Inc. | 24 | $512 |
| AbbVie | 38 | $483 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 15 | $309 |
| Otsuka America Pharmaceutical, Inc. | 10 | $201 |
| Lundbeck LLC | 8 | $154 |
| Johnson & Johnson | 7 | $123 |
| Corium, LLC | 8 | $112 |
| Teva Pharmaceuticals USA, Inc. | 5 | $105 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $105 |
| Axsome Therapeutics, Inc. | 6 | $103 |
| E.r. Squibb & Sons, L.L.C. | 1 | $88 |
| Neurocrine Biosciences, Inc. | 6 | $86 |
| Sunovion Pharmaceuticals Inc. | 6 | $75 |
| Janssen Scientific Affairs, LLC | 1 | $57 |
| Merck | 3 | $46 |
| Idorsia Pharmaceuticals US Inc | 3 | $43 |
| Tris Pharma Inc | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$311
How this compares
$3,258 in reported general payments places this provider in the 80th percentile of 404 psychiatric/mental health providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 13 | $37,205 |
| LybalviOlanzapine/Samidorphan Malate | 20 | $33,133 |
| VraylarCariprazine Hcl | 16 | $21,925 |
| QelbreeViloxazine Hcl | 11 | $8,045 |
| TrintellixVortioxetine Hydrobromide | 14 | $6,530 |
| Aripiprazole | 18 | $3,733 |
| Divalproex Sodium ErDivalproex Sodium | 55 | $2,509 |
| Naltrexone Hcl | 12 | $1,142 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 24 | $1,041 |
| Clozapine | 35 | $900 |
| Olanzapine | 75 | $876 |
| Paliperidone ErPaliperidone | 11 | $840 |
| Quetiapine Fumarate | 42 | $839 |
| Trazodone Hcl | 45 | $454 |
| Sertraline Hcl | 90 | $445 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $123 | $37,20513 claims |
| Alkermes, Inc.Lybalvi | $637 | $33,13320 claims |
| AbbVieVraylar | $483 | $21,92516 claims |
| Supernus Pharmaceuticals, Inc.Qelbree | $512 | $8,04511 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $105 | $6,53014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 404 psychiatric/mental health providers in Kansas.
Other psychiatric/mental health in Manhattan
- Roger KirkwoodManhattan$6K
- Eric ThomasonPittsburg$333K
- Belinda BagbyHutchinson$39K
- Hayley KnappWichita$31K
- Jennifer KubinBaldwin City$26K
- Uyen DinhPittsburg$20K
- Louise MuhoziKansas City$14K
- Theresa MuellerOverland Park$14K
- Shiney ZchariaOlathe$14K
- Deborah MurphyWichita$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.